Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 2:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 8,193 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Results available

PLATINUM Diversity

NCT02240810
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
Percutaneous coronary intervention (Promus PREMIER)
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
52
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 48 more
Conditions
Bone Mineral Density
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
12 Years to 18 Years · Female only
Enrollment
1,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 39 more
Conditions
COVID-19, Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Lichen Sclerosus
Interventions
Delgocitinib, Cream Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 18 more
Conditions
Inclusion Body Myositis (IBM)
Interventions
Ulviprubart (ABC008)
Drug
Lead sponsor
Abcuro, Inc.
Industry
Eligibility
40 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 14 more
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 13 more
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 31 more
Conditions
Breast Reconstruction, Revision Breast Reconstruction
Interventions
Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Device
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
77
States / cities
Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 66 more
Conditions
Lung Preservation
Interventions
OCS Lung, Cold flush and storage
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309
Conditions
Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
Interventions
Not listed
Lead sponsor
Marinella Temprosa
Other
Eligibility
Not listed
Enrollment
1,976 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
Conditions
Hepatitis C
Interventions
Telaprevir, Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
3 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 10 more
Conditions
Parkinson's Disease With End of Dose Wearing Off
Interventions
Carbidopa/levodopa/entacapone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Fullerton, California • Irvine, California + 38 more
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 78 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Redlands, California • Tustin, California + 9 more
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel
Drug
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 29 Years
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Culver City, California • Irvine, California + 16 more
Conditions
Medulloblastoma, Central Nervous System Embryonal Tumors
Interventions
Induction, Single Cycle Intensive Chemotherapy, Tandem 3 Cycle Intensive Chemotherapy
Drug
Lead sponsor
Parth Patel
Other
Eligibility
Up to 10 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Active, not recruiting Phase 2 Interventional

Preventing Asthma in High Risk Kids

NCT02570984
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
24 Months to 47 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Aurora, Colorado + 10 more
Conditions
Non Small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
Active, not recruiting Not applicable Interventional

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

NCT03706833
Conditions
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Interventions
Edwards PASCAL System, Abbott Mitraclip System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Active, not recruiting Not applicable Interventional

EDX110 Randomized Control Trial for Treatment of DFUs

NCT07209358
Conditions
Wound Heal, Diabetic Foot Ulcer
Interventions
EDX110
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 6 more